Visilizumab
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research[1].
Product Specifications
CAS Number
[219716-33-3]
Product Name Alternative
Anti-Human CD3E Recombinant Antibody; HuM291
UNSPSC
12352203
Target
Apoptosis
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/visilizumab.html
Purity
99.49
Solubility
10 mM in DMSO
Smiles
[Volociximab]
Molecular Weight
(144.66 kDa)
References & Citations
[1]Qi T Yu, et al. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun;127 (3) :322-9.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
